Appearance of neointima according to stent type and restenotic phase: analysis by optical coherence tomography

Goto, Kenji; Takebayashi, Hideo; Kihara, Yasuki; Hagikura, Arata; Fujiwara, Yasukazu; Kikuta, Yuetsu; Sato, Katsumasa; Kodama, Sunao; Taniguchi, Masahito; Hiramatsu, Shigeki; Haruta, Seiichi

doi:10.4244/eijv9i5a96

Cited by 20 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that most cases of ISR involving bare metal stents (BMSs) have a homogeneous pattern (91%) in the early phase. (6) This implies that the arterial healing process starts smoothly in the early phase following BMS implantation. The American College of Cardiology/American Heart Association guideline mentioned that dual antiplatelet therapy should be continued for at least six months after the implantation of secondgeneration DESs.…”

Section: Discussionmentioning

confidence: 99%

In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents

Kajiya¹,

Yamaguchi²,

Takaoka³

et al. 2019

smedj

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents

Kajiya¹,

Yamaguchi²,

Takaoka³

et al. 2019

smedj

View full text Add to dashboard Cite

show abstract

“…To date, the mechanisms and characteristics of late stent failure have not been fully understood. Previous studies [33][34][35] have reported diabetes mellitus, stent type, diameter, and length were associated with stent failure. Our present findings suggest, within the limits of a small scale exploratory trial, a number of independent predictors for stent failure.…”

Section: Predisposing Factors For Stent Failurementioning

confidence: 91%

Association of stent‐induced changes in coronary geometry with late stent failure: Insights from three‐dimensional quantitative coronary angiographic analysis

Zhang

Καρανάσος³

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Mechanical pullback at a speed of 20 mm/s was started during continuous automatic flushing of 2–5 mL/s of iodixanol (Visipaque™ 320 mg I/mL, GE Healthcare, Amersham, UK), using a Medrad injector (Medrad Inc., Warrendale, PA, USA), to ensure blood clearance from the coronary arteries. Quantitative measurements included lumen and stent cross‐sectional areas (CSA) (automatically traced and manually adjusted when required), neointimal hyperplasia (NIH) area (i.e., stent area minus lumen area), and percentage of NIH area (NIH area/stent area × 100) …”

Section: Methodsmentioning

confidence: 99%

Bilirubin coating attenuates the inflammatory response to everolimus‐coated stents

et al. 2017

View full text Add to dashboard Cite

The aim of this study was to evaluate the effects of bilirubin- and/or everolimus (EVL)-coated stents to prevent arterial neointimal hyperplasia and inflammation in vitro and in vivo. The stents were prepared by spray coating bare metal stents (BMS) with bilirubin and/or EVL. Study groups were divided into (1) BMS, (2) bilirubin-coated stents (BES), (3) commercialized stents (Synergy™; EES), and (4) bilirubin/EVL-coated stents (B-EES). The coating thickness and drug release rates were comparable to previous reports (i.e., <4 µm thickness and 50% drug release in 7 days). Smooth muscle cell migration was inhibited in both EVL-containing groups (20.5 ± 3.80% in EES and 18.4 ± 2.55% in B-EES) compared to the non-EVL-containing groups (78.0 ± 6.41% in BMS and 76.1 ± 4.88% in BES) (n = 10, p < 0.05). Stents were randomly implanted to 40 coronary arteries in 20 pigs and subjected to various analyses after 4 weeks of implantation. As results, the inflammation score was dramatically increased in the EES group (2.1 ± 0.42) compared to that of the other groups (1.5 ± 0.55, 1.3 ± 0.23, and 1.5 ± 0.27 for BMS, BES, and B-EES, respectively, n = 10, p < 0.05). Immunofluorescence analysis revealed that inflammation was prevented in the bilirubin-containing groups (BES and B-EES). However, the percent area of restenosis was decreased in the EVL-containing groups (20.5 ± 4.11% for EES and 18.4 ± 3.61% for B-EES) compared to the non-EVL-containing groups (32.3 ± 6.41% for BMS and 29.6 ± 5.95% for BES, n = 10, p < 0.05). The percent areas of restenosis determined by histopathology, optical coherence tomography, and micro-computed tomography were consistent. In addition, the stent was barely covered in the EES and B-EES groups at 4 weeks postimplantation. These dual drug-coated stents may be especially beneficial to patients who have an increased risk of inflammation. These stents have great potential for use in cardiovascular applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1486-1495, 2018.

show abstract

Appearance of neointima according to stent type and restenotic phase: analysis by optical coherence tomography

Abstract: There were differences of neointima according to stent type and restenotic phase, and this may lead to a better understanding of the different mechanisms of ISR.

Cited by 20 publications

References 26 publications

In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents

In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents

Association of stent‐induced changes in coronary geometry with late stent failure: Insights from three‐dimensional quantitative coronary angiographic analysis

Bilirubin coating attenuates the inflammatory response to everolimus‐coated stents

Contact Info

Product

Resources

About